3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
33
Breast Neoplasms
26
Triple Negative Breast Neoplasms
17
Prostatic Neoplasms
16
Fallopian Tube Neoplasms
11
Neoplasms
9
Fanconi Anemia, Complementation Group D1
7
Endometrial Neoplasms
7
Pancreatic Neoplasms
6
Glioma
6
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Small Cell Lung Carcinoma
5
Sarcoma
5
Neoplasm Metastasis
5
Cholangiocarcinoma
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Lymphoma, Non-Hodgkin
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Breast Cancer
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Osteosarcoma
3
Lung Neoplasms
3
Glioblastoma
3
Colorectal Neoplasms
3
Carcinosarcoma
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Interventions
Doxorubicin
6
Trabectedin
5
pazopanib
4
Radiotherapy
4
ribociclib
3
pembrolizumab
3
palbociclib
3
Gemcitabine
3
brostallicin
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Immunoglobulin G
2
Imatinib Mesylate
2
Ifosfamide
2
Docetaxel
2
Dexamethasone
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zimberelimab
1
temsirolimus
1
tanespimycin
1
talimogene laherparepvec
1
sotigalimab
1
soblidotin
1
sitravatinib
1
saracatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Liposarcoma
×
olaparib
×
Clear all
NCT06116578
2025-12-01
NeoSarc
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Withdrawn